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NIJmerWs clinical reports have documented an increase in t.r'cuJh blood 
conoentratiCl'lS of cyclosporine in transplant recipients treated 
con::xJ!\itantly with ketocxmazole. '!be objective of this stuiy was to 
elucidate the mechanism(s) un:ierlyin;J the cyclosporine-ketoconazole 
interaction usin;J a choledoc:::halreteros dog IOOdel.. Five male beagle 
dogs received a 4 nqj1cg, Lv. bolus dose of cyclosporine either alone 
or on day seven of a 10-day, 13 nq/Jcg/day, oral closin;J reg:iJnen of 
ketoc:x:rlazole. Blood sanples were collected prior .. t;o. and at 
predeteI1nined times for 60 hrs after the cyclosporine dose, while the 
bile/urine mixture was collected quantitatively for 96 boors after the 
cyclosporine dose. Ketooonazole decreased the systemic clearance of 
cyclosporine frau 7.0 ml/lninlkg to 2.5 mljlnin.lkg. '!he tenninal 
disposition rate constant was also decreased significantly fran 0.0794 
to 0.0354 hrs-1 • Ketoc::lonaZole caused no significant charges in 
cyclosporine steady state volt.une of distribltion, or plasma llJ'lboun:i 
fraction. Ketocx:nazole did not significantly alter the excretion of 
cyclosporine and varioos cyclosporine metabolites in the bile/urine 
mixture. Inhibition of hepatic dJ:u;J metabolizin;J enzymes ~ to be 
the primary reasal for the ketoccnazole imuoed elevation in 
cyclosporine cxn::leJ rtration. 
INImll.JCl'IQf 
cyclosporine (C'iA) is a unique i.nm.Jnc:lsuwressant used to prevent 
the rejection of transplanted organs and to treat diseases of 
autoimmune origin. cyclosporine is a neutral cyclic polypeptide 
oonsistin;J of 11 amino-acids (Figure 1). cyclosporine u:rrlergoes 
extensive hepatic metabolism in humans and animals. '!he 
biotransfonnation pathWay of C'iA is qualitatively similar in all the 
animal species st::ldied. (Beverid;Je, 1982: Maurer ~. , 1984 : 
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Venkataramanan, 1988). Of the 17 suspected metabolites of aA, 11 have 
been isolatecl ani identified (Maurer ~., 1984). All the identified 
metabolites have the intact cyclic oligcpeptide structure of the parent 
drug. Structural nalificaticms durin;J metabolism iD:lu::Je JIItIlO- am 
dihydraxylatim as wll as N-demethylatiext (Figure 1). Isss than 1\ of 
the administered dose of aA is excreted in the bile as parent drug 
while greater than 4n of the dose ~ as aA metabolites 
(Venkataramanan 1985a: Wood ~., 1983). Patients ~ receive aA 
nay require antifun;Jal therapy. Ketocalazole is an orally active 
antifun;Jal drug. Recent clinical reports bdicate marked irx:reases in 
blood t.n:u;Jh c:x:n:srtration of aA alCD;J with an in::rease in serum 
creatinine in transplant recipients treatecl caxxmitantly with 
ket:cc:alazole (lob:ger1St:em ~. , 1982; Fergusal ~. , 1982; 
Dieperink ani Jt:)ller, 1982: l>I1ite ~., 1984). Hcwaver the 
mec:bani.sa& urderlyin;J this int:eractim have oot: been OCIIpletely 
characterized. 
'lhe objective of the present study was to oc:aprehensively examine 
the effect of ketcx::alazole at the plasma protein binii.n.J, hepatic 
metabolism, ani biliary excretim of aA. 
Qnicals: 
Cyclosporine (samilmune Injectable - 8amoz) ani ket:cIcx:mzol.e 
(Nizoral tablets - Janssen) wre p.II'dmsed frail CCIIIIIBl'Ci.al sources. 
Cyclosporin 0 ani cyclosporin G wre gifts frail Samoz, Inc. other 
c:hemicals ani solvents wre pm:hased frail Fisher Scientific CO. 
(Fairlawn, H1) ani wre of ACS reagent grade ani HPIC grade, 
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The stu:iy was perfonned in five male beagle dogs ~i~ between 
13.5-18.0 kg. A dvJledodlcm:et:eros was perfonned in all five dogs 
awraximately six JI01ths prior to the present stu1y. '!he a::mtal bile 
duct was ligated close to the c::hxrlenJm am cxxal9Cteci to the ur:i.naIy 
black:ier usin;J a plastic stent. In the c:x:ntrol (base the dogs received 
a 4 nqIJcg i. v. bolus dose of crA t:hrtugh a catheter placed in the 
fE!IDral leg vein. In the treatment IilaSe the dogs received a 13 
nq/kg/day oral dose of ket.c:x:xxlazole for 10 days. On day seven of 
ketoconazole therapy the dogs received a 4 nq/1cg, Lv. bolus dose of 
CiA, one hrur after the regular daily dose of ketooonazole. In both 
pw;es of the stu:iy, the dogs \oIet"e fasted for 14 boors prior to am. for 
foor halrs after the C'lA dose. A one week washcut period was allaNed 
Intravenoos C'lA solutions \Were freshly 
prepared 00 the day of the stu1y by dilutinj the cx:mnercially 
available preparatioo (sardilImme'IM r. V.; sandoz Inc., Basel, 
SWitzerlam) with sterile saline. Ket.occmzole was administered orally 
as a suspensioo. CcmDercially available tablets (Nizoral'IM; Janssen 
Fbarmaoeutica Inc., Belgium) \oIet"e crushed in a mrtar am. fornul.ated 
into a suspensioo with si.q>le syrup. 
Blood was sanpled before am at 0.25, 0.50, 1.0, 2.0, 4.0, 6.0, 
8.0, l2.0, 15.0, 24.0, 36.0, 48.0 am 60.0 hrs after the C'lA 
administration. Blood sauples were stored at -20·C pen:tin;J high 
pressure liquid c::hranat:oc;JraPU.c (HPlC) analysis for intact crA. An 
aliqJot of the blood semple was ~, plasma collected am. 
stored at -20·C ~ HPLC analysis for intact ket:oc:xrla.zole. 
443 
- --- --------- ~--.------------------~. ~ - - - -
VOL. 64, NO.3 
JUNE 1989 
Research Communications in 
Chemical Pathology and Pharmacology 
Bile/urine mixt:ure was collected quantitatively us~ a metabolic cage 
in 12 hr intervals, for 96 hrs after the C'iA dose. Bile/urine sa!!ple 
volumes were ueasured, ani an aliquot stored at -20'C perxii.n;J analysis 
for intact C'fA ani C'iA met.al:x>lites. Bioc::hemical irxtices of liver 
functioo was ueasured in all five dogs dur~ both pw;es of the sb:dy. 
In vivo plasma protein birx:1in;J of C'fA was dete:tmined fran erythrocyte 
partitionin;J measurerrents us~ the proaedure described by Tl:urg ~. 
(1984). 
cyclosporine conoentratioo in blood saDples were measured us~ a 
specific am sensitive HPIC methcxi (ptadlcinski ~., 1985) while 
ket.ocalazole ooncentrations were neasured by the HPIC method of Badcock 
(1984). '!he metabolites of CY.A were separated us~ a high pressure 
liquid dlranatcgrapric gradient elutioo system devel.cped in 0lI' 
laboratory. six ether extractable metabolites were separated us~ a 
solvent system oa'lSist~ of a linear gradient of aoet:aritrile am 
water startin::J at 35% acetonitrile am in::reas~ to 67% acetonitrile 
CNe:r 65 minItes. '!he JOObile Jilase was p.mp:rl thl:"cu;Jh the column at a 
flow rate of 1.7 ml/min. '!he extractioo ani other dlranatograpric 
cxnti.tions enployed were silllilar to those enployed for the analysis of 
parent C'fA. since adequate quantities of pJre metabolites were not 
available for cxrstruction of stardard. calibratioo plots it was not 
possible to quantitate the absolute aDO.Il'lts of the metabolites. 
'Iherefore, peak area ratios of each of the metabolites to the intemal 
standard were calculated for each sanple. 'lbese values were normalized 
for differeooes in the total volume of bile/urine mixture excreted by 
the five dogs dur~ each Jilase of the sbXty. 'lbese nozmalized values 
were Sllbsecp!ntl.y cxrwerted to cycl.osporine equivalents am used to 
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Figure 1. structure of cycl.osporine am. its metabolites. 
o:::apm! the effect of ketoccnazole en the metal:lolic profile of CYA. 
M:del imEpeldent }i\annacokinetic parameters for CYA includinq the 
teminal dispositien half-life (Tl/2)' total body clearance (CL), 
intrinsic clearance (Clu int), am steady state volume of distribltien 
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Differences in JOOdel i.n::\epement ~c 
parameters between the control and treatment groups 'WIIE!l"e evaluated 
us~ the Sbldents paired t-test at a significant level of 0.05. 
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Figure 2. Cyclosporine blood CXllCel'ltratial versus time profile in dog 
'4 before (0) an:! dur~ (0) ket:ocalazol.e treatment. Each dog received 
4 nq/J<g of cycl.osporine as an int.ravencuJ bolus injectial. 
Figure 2 shews the CiA blood CXlk:leIttratial time profile before an:! 
durin:} ketcocnazole treatment in dog l'IJIIiler 4, \r4lile Table 1 SUIIIMrizes 
the effect of ket:ocalazole al CD. dispositial in five dogs. 
Ketcx:x:nlzole caused a significant drecreI!Ise in the systEmic clear:an::l8 of 
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Table 1 
Mean cyclosporine Iilannaookinetics in five dogs before 
an:l durirn ketocxl'lazole tI"eatmrt: 
Treatment, Mean ± S.D. 
Parameter cycJ.osporine cycl.osporine 
(units) Alooe + I<et:ocx:n1zole 
1) Dispositioo 8.7a 19.5 
Half-Life (hrs) 
2) "2 (halrs-1) 0.0794 ± 0.033 0.0354 ± 0.022 
3) o.mulative ADnmt 0.19 ± 0.10 0.40 ± 0.25 
Excreted (ng) 
4) Clearance 7.0 ± 3.6 2.5 ± 1.5 
(ml./mi.n,IJ<g) 
5) Plasma Free 0.090 ± 0.05 0.16 ± 0.10 
Fractioo 
6) Intrinsic 69.70 ± 10.0 6.72 ± 1.8 
Clearance 
(ml/lD.inlng) 
7) steady state Volume 4.0 ± 0.8 4.4 ± 1.6 
of DistribJtioo 
(IIJcg) 
~cmean 
P 
Value 
0.005 
N.S. 
0.013 
N.S. 
0.001 
N.S. 
CiA fran 7.0 ml,lmi.n,l.kq to 2. 5 ml/Ini.rVJaJ with a pxcportiooate increase 
in its half-life fran 8.7 to 19.5 hoors. Ketoc:a1azole also caused a 
narked decrease in C'lA intrinsic clearance fran a mean of 67.7 
ml/Ini.rVJaJ to 6.7 ml.,/lnin/J<g. 'lbere was no statistically significant 
c:han:.Je in CiA plasma protein or its steady state volume of 
ctistrib.Itioo • 
Ket.oc:x:I'lazole caused a 17-56\ decrease in the levels of three of 
the six CiA mtabolites Crable 2). Si:aultanecA.ls, am prOOably 
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Table 2 
Effect of ketcxxmzole en the 1lf!P!lnlic 
profile of cyclosporine in dogs 
Treatment, Mean ± S.D.b,e 
cycl.osporine cycl.osporine 
Alene + Ketooc:nazoled 
2.4 ± 1.1 3.7 ± 1.7 
0.44 ± 0.2 0.55 ± 0.4 
1.7±O.5 2.2 ± 0.7 
0.92 ± 0.3 0.77 ± 0.3 
2.7 ± 1.2 1.S ± 1.1 
1.1 ± 0.3 0.56 ± 0.5 
~er to Figure 1 for detailed structure of the met:aJ:x)lites. 
~- 5 
OValues are expressed as cyclosporine equivalents. 
dtkna of the parameters are statistically different (p < 0.05). 
oc:.IIpE!llSatory increases ~ d:Jserved in the levels of metabolite 
f'ILIIIi)ers 21, 18 ani 1. However, ncne of these c:har¥;Jes loIere 
statistically significant prdlably as a ca'lSE!qIlellOe of the variability 
in the data. 
Figure 3 sha.Is the Jcetocalazole plasma (Xn::entraticn-time profile 
in dog 1 en day 7 of the treatment pericxl. Peak plasma ccn:Jel'ltratioo 
of 9.3 J,Ig/Inl was readled between 2 to 3 hours after the oral dose. 
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Figure 3. Ket:occm.zole plasma <XIlOe11tratioo-time profile in dog #1 on 
day 7 of a 10 day 13 l!g/1<g/day oral dosirg :regimen. 
DISaJSSICN 
Ket:oconazole is a known inhibitor of microsaDal. enzymes in the rat 
(Niemegeers ~., 1981; Sheets am Masal, 1984; Meredith ~., 
1985) am humans (Brown~., 1985; rBneshmen:i ~., 1983). Recent 
st:uties in man have shewn that ketc::Icxnazole has no effect CXl 
theq:hylline clearaooe whereas the dnJ:} decreases chlordiazep:ncide 
plasma clearance leadirg the authors to cx::nclu:ie that ketooonazole 
inhibits at least one subset of the hepatic mixed f'llrx:tiCXl oxidase 
systen (Brown et al., 1985) • CoadministratiCXl of ketooonazole 
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irx:reases the serum C'iA cx:.noentrations in transplant patients 
(lomgeust:em ~., 1982; Dieperink ani ~ller, 1982; White ~., 
1984: GuDbleton et al., 1985). Recently the interaction of C'iA ard 
ketoocnazole was sb.xtied in mice (Amerson ard Blaschke, 1986) • A 
significant increase in the half life ani a reduction in the cleararx:e 
of C'iA was ci:lseIvecl in these arWna1s. F\lrther stu:iy by the sane graJp 
of investigators documents potentiation of the ~ive effect 
ani toxicity of C'iA in mice reoeivin;J ketcx:x:rlazole (An::lersal~., 
1987) • However the stu:iy was c:::orrlucted in two separate groJpS of 
animals ard the ~ of large interin:li.vidual variations in the 
kinetics of C'iA ooo.ld potentially influence the conclusions of the 
sbxly. siIxJe C'iA plasma protein bi.rdin:J was not detennined in these 
animals, the actual medlanism(s) responsible for the d:Iserved decrease 
in the total clearaoce ooo.ld not be detennined. 
In the present study, the sanv:! animals \olere used in the centrol 
ani treat:nent tnase of the stu:iy. studies were romucted in dogs with 
c:holedoc::houretero. 'lhi.s enables carplete rollection of bile ard 
the urine for the quantitative detennination of C'lA ard its 
metabolites. '!be mean cleanm::e, plasma protein birdin;J, ard half life 
of C'lA in these dogs was similar to what has been reported in the 
literature (Venkataramanan ~., 1987). 'lhi.s inticates that 
c:holodedlo.lreteros had no significant effect on the dispositioo of 
C'iA. '!be effect of cholodectlalreterostany on the clispositioo of 
ketoocnazole was not examined in this stu::ly. '!be extent of inhibitioo 
of dJ:ug metabolizin;J enzymes is expected to be a function of the 
cx:n::entratioo of the inhibitor. '!be mean peak ketocx:lnazole plasma 
cx:n::entrations of 13.1 J.IC1IlIIl that was observed in the five dogs in this 
450 
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stldy was CX1IpU'able to that reported by Baxter ~. (1986) 
inllcat.:irg that c:holedoc:hc:met:ero prci)ably had a minimal. effect on 
the disposition of ketoconazole in these an.i.mal.s. 
Ket:oc:xI'lazole treatment resulted in a significant decrease in the 
intrinsic clearance of C'lA in dogs. A stldy in human liver microsanal. 
i.rx:ubates has shcwn that ket:cxxlnazole inhibits the metabolism of C'lA. 
A Michaelis-Menten plot of the data inllcated a mixed type of 
inhibition (Mauer, 1985) • Pretreatment with ketocx:nlzole prOOably 
inhibited the oxidative enzymes respaasible for C'lA metabolism which in 
tum aocnmts for the ci:lselved decrease in its intrinsic clearance in 
the five dogs. IacJt of artf significant difference in the anamt of 
parent C'lA am various metabolites excreted in the bile/urine mixture 
durin; the t'NO different pmses in:iicates no selective inhibition of 
artf specific pathways of C'lA elimination by ketocx:nlzole in dogs. 
Earlier stuiies have ~ that ketcoonazole is a potent am 
specific inhibitor of N-demethylase activity in humans am animals 
(Brown ~., 1985: Sheets am MascI'l, 1984: Meredith ~., 1985). 
Ket:oc:xI'lazole treatment has been asscx::iated with silent am 
syuptanatic hepatic reactialS. '!he effect of ket:cxx:r\azole on the liver 
rarges fran asyaptanatic transient elevatioos of serum transaminase or 
alkaline }ilcsPlatase to potentially fatal aaIt:e necrcsis, ani may ocx:ur 
at artf time durin; ketcccnazol.e treatment (Lewis ~., 1984). 
cycJ.osporine clearance has been shewn to be i:Dpaimd in patients with 
liver disease (Venkataramanan ~., 1985b) am in dogs with 
experimentally imuced hepatic dysfunction (Takaya ~., 1987). It 
is therefore possible that the decrease in C'lA clearance durin; 
ketoca'lazole treatment cxW.d be partly due to hepatic injury associated 
451 
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HoWever, bioc:hemi.cal indices of 
liver f'Ur¥::tioo reveal that ketocxlnazole treatment caUSEd 00 d'laJ'9! in 
the fur¥::tiooal integrity of the livers of the animals (data not shewn). 
'lberefore the decrease in C'iA clearance durin; ket:cx::alazole therapy is 
primarily due to ketocanazole i.rmJced inhibitioo of the oxidative 
enzymes respalSible for C'iA uetabolism. 
In cxn:llusioo, the results of this investigatioo daoonstrate that 
ket:ocx:I1azole decreased the systemic clearance of C'iA probably as a 
~ of an inhibition of C'iA metabolizin; enzymes. Ket:ooooazole 
caused 00 c::har¥3e in the distrib.Itioo of C'iA in dogs. si.roe C'iA is a 
10117 clearance ciru3' in dogs, a decrease in its intrirlSic clearance woold 
lead to an increase in the coocent:ratioo of the llJ'lba.ni, 
pw:uacologically active species. A similar medlanism may also be 
rE!SIXIlSible for the :in::reased JlE!Ifu'otaxicity d:lselved in transplant 
recipients treated cx:n:x:mi.tantly with ketcx:la1azole. 
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